Advanced

Linked clinical trials - the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments

Brundin, Patrik; Barker, Roger A LU ; Conn, P Jeffrey; Dawson, Ted M; Kieburtz, Karl; Lees, Andrew J; Schwarzschild, Michael A; Tanner, Caroline M; Isaacs, Tom and Duffen, Joy, et al. (2013) In Journal of Parkinson's Disease 3(3). p.9-231
Abstract

Finding new therapies for Parkinson's disease (PD) is a slow process. We assembled an international committee of experts to examine drugs potentially suitable for repurposing to modify PD progression. This committee evaluated multiple drugs currently used, or being developed, in other therapeutic areas, as well as considering several natural, non-pharmaceutical compounds. The committee prioritized which of these putative treatments were most suited to move immediately into pilot clinical trials. Aspects considered included known modes of action, safety, blood-brain-barrier penetration, preclinical data in animal models of PD and the possibility to monitor target engagement in the brain. Of the 26 potential interventions, 10 were... (More)

Finding new therapies for Parkinson's disease (PD) is a slow process. We assembled an international committee of experts to examine drugs potentially suitable for repurposing to modify PD progression. This committee evaluated multiple drugs currently used, or being developed, in other therapeutic areas, as well as considering several natural, non-pharmaceutical compounds. The committee prioritized which of these putative treatments were most suited to move immediately into pilot clinical trials. Aspects considered included known modes of action, safety, blood-brain-barrier penetration, preclinical data in animal models of PD and the possibility to monitor target engagement in the brain. Of the 26 potential interventions, 10 were considered worth moving forward into small, parallel 'learning' clinical trials in PD patients. These trials could be funded in a multitude of ways through support from industry, research grants and directed philanthropic donations. The committee-based approach to select the candidate compounds might help rapidly identify new potential PD treatment strategies for use in clinical trials.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
publishing date
type
Contribution to journal
publication status
published
keywords
Antiparkinson Agents, Clinical Trials as Topic, Humans, Parkinson Disease, Prospective Studies, Journal Article, Review
in
Journal of Parkinson's Disease
volume
3
issue
3
pages
9 pages
publisher
IOS Press
external identifiers
  • scopus:84888869235
ISSN
1877-718X
DOI
10.3233/JPD-139000
language
English
LU publication?
no
id
07b403dc-8fc0-4e09-a7c1-4fcbb599fc04
date added to LUP
2016-11-24 15:17:15
date last changed
2018-01-07 11:36:55
@article{07b403dc-8fc0-4e09-a7c1-4fcbb599fc04,
  abstract     = {<p>Finding new therapies for Parkinson's disease (PD) is a slow process. We assembled an international committee of experts to examine drugs potentially suitable for repurposing to modify PD progression. This committee evaluated multiple drugs currently used, or being developed, in other therapeutic areas, as well as considering several natural, non-pharmaceutical compounds. The committee prioritized which of these putative treatments were most suited to move immediately into pilot clinical trials. Aspects considered included known modes of action, safety, blood-brain-barrier penetration, preclinical data in animal models of PD and the possibility to monitor target engagement in the brain. Of the 26 potential interventions, 10 were considered worth moving forward into small, parallel 'learning' clinical trials in PD patients. These trials could be funded in a multitude of ways through support from industry, research grants and directed philanthropic donations. The committee-based approach to select the candidate compounds might help rapidly identify new potential PD treatment strategies for use in clinical trials.</p>},
  author       = {Brundin, Patrik and Barker, Roger A and Conn, P Jeffrey and Dawson, Ted M and Kieburtz, Karl and Lees, Andrew J and Schwarzschild, Michael A and Tanner, Caroline M and Isaacs, Tom and Duffen, Joy and Matthews, Helen and Wyse, Richard K H},
  issn         = {1877-718X},
  keyword      = {Antiparkinson Agents,Clinical Trials as Topic,Humans,Parkinson Disease,Prospective Studies,Journal Article,Review},
  language     = {eng},
  month        = {01},
  number       = {3},
  pages        = {9--231},
  publisher    = {IOS Press},
  series       = {Journal of Parkinson's Disease},
  title        = {Linked clinical trials - the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments},
  url          = {http://dx.doi.org/10.3233/JPD-139000},
  volume       = {3},
  year         = {2013},
}